Hikal Q2 FY27 Revenue ₹434 Cr, PAT ₹(6) Cr

Hikal Ltd announced its unaudited financial results for the quarter and half-year ended September 30, 2026. Revenue for Q2 FY27 stood at ₹434 crore, with EBITDA at ₹45 crore and margins of 10.3%. Profit After Tax (PAT) was ₹(6) crore. The Pharmaceuticals business saw a significant YoY revenue growth of 47% to ₹278 crore, driven by API recovery and CDMO expansion. The Crop Protection business revenue grew 21% YoY to ₹156 crore, despite operating challenges. Key developments include the successful conclusion of a Swissmedic inspection, commencement of commercial production at the new Panoli facility for Personal Care, and signing a multi-year CDMO contract with a European agrochemical company. The company anticipates improved performance in H2 FY27.